



Product Information

Bcr-Abl inhibitor DCC-2036, Purity $\geq 98\%$

Cat. No.: X24-06-ZQ444

Size: 5 mg; 10 mg; 50 mg; 100 mg


MDL: MFCD19443646

CAS Number: 1020172-07-9

Compound CID: 25066467

Synonym: 1020172-07-9; Bcr-Abl inhibitor; DCC2036

This product is for research use only and is not intended for diagnostic use.



Product Information

Description	DCC-2036, soluble in DMSO and ethanol and insoluble in water, specifically inhibits the activity of the Bcr-Abl tyrosine kinase. It targets Abl1 (H396P), p-Abl1 (native), AuroraA, c-Kit, CDK2/CyclinD, FGR, FLT3, HCK, KDR, Lyn, and p-Abl1(T315I).
Molecular Weight	553.59
Molecular Formula	C ₃₀ H ₂₈ FN ₇ O ₃
Targets	Abl1 (H396P): 1.4 nM; p-Abl1 (native): 2 nM; AuroraA: >5 μ M; c-Kit: 481 nM; CDK2/CyclinD: >5 μ M; FGR: 38 nM; FLT3: 2 nM; HCK: 40 nM; KDR: 4 nM; Lyn: 29 nM; p-Abl1 (T315I): 4 nM
IUPAC Name	4-[4-[(5-tert-butyl-2-quinolin-6-ylpyrazol-3-yl)carbamoylamino]-3-fluorophenoxy]-N-methylpyridine-2-carboxamide
InChI	InChI=1S/C30H28FN7O3/c1-30(2,3)26-17-27(38(37-26)19-7-9-23-18(14-19)6-5-12-33-23)36-29(40)35-24-10-8-20(15-22(24)31)41-21-11-13-34-25(16-21)28(39)32-4/h5-17H,1-4H3,(H,32,39)(H2,35,36,40)
InChI Key	WVXNSAVVKYZVOE-UHFFFAOYSA-N
Canonical SMILES	<chem>CC(C)(C)C1=NN(C(=C1)NC(=O)NC2=C(C=C(C=C2)OC3=CC(=NC=C3)C(=O)NC)F)C4=CC5=C(C=C4)N=CC=C5</chem>
Form	Lyophilized powder
Purity	$\geq 98\%$
Solubility	DMSO: 103 mg/mL (186.05 mM); Water: Insoluble; Ethanol: 15 mg/mL (27.09 mM)
Identity	Confirmed by NMR/HPLC/MS.
Stability	The product is stable for three years when stored at the recommended temperature in lyophilized



powder.

Quality Level

Research grade

Applications

DCC-2036 offers a framework for researching alternative therapies to overcome resistance in chronic myeloid leukemia.

Storage

Store at -20°C, and keep desiccated.
